A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Phase 2

Recruiting

• Conditions: Idiopathic Hypersomnia
• Interventions: Drug: TAK-360; Other: Placebo

• Registration Number: NCT06812078
• Lead Sponsor: Takeda

Brief Summary

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake.

The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that.

Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-03
• Study First Submitted QC: 2025-02-03
• Study First Posted: 2025-02-06
• Study Start: 2025-02-07
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-09
• Last Update Posted: 2025-05-11
• Primary Completion: 2026-02-19
• Study Completion: 2026-02-19

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. The participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m^2) [inclusive].
2. The participant has a documented, current diagnosis of IH.

Key

Exclusion Criteria

1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) [other than IH].
2. The participant has medically significant thyroid disease.
3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ [such as basal cell carcinoma] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor.)
4. The participant has any of the following viral infections based on a positive test result: Hepatitis B surface antigen (at screening), hepatitis C virus antibody (at screening), human immunodeficiency virus (HIV) antibody/antigen (at screening).
5. The participant has a clinically significant history of head injury or head trauma.
6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
7. The participant has a history of cerebral ischemia, transient ischemic attack (less than [<]5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TAK-360	TAK-360	Participants will receive TAK-360 tablets, orally, for 4 weeks.
Placebo	Placebo	Participants will receive TAK-360 matching placebo tablets, orally, for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)	Up to Week 8	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

Secondary Outcome Measures

Name	Time	Method
Change from Baseline at Week 4 in Epworth Sleepiness Scale (ESS) Total Score	Baseline, Week 4	The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.
Change from Baseline at Week 4 in Idiopathic Hypersomnia Severity Scale (IHSS) Total Score	Baseline, Week 4	IHSS is a 14-item self-assessment questionnaire, to measure the severity, frequency and functional impact of the three key IH symptoms (during a recall period of "past 7 days"). The IHSS includes 14 items in total; two items (1 and 2) on nighttime sleep duration and quality, three items (3, 4 and 5) on sleep inertia and sleep drunkenness after nighttime sleep and one (8) after daytime nap, and three items (6, 7 and 9) on diurnal symptoms (nap occurrence, daytime sleepiness). Items 10 to 14 assess daytime functioning alterations due to hypersomnolence. Six items are scored on a 3-point Likert scale and eight items on a 4-point Likert scale; the Likert scale is a point scale which is used to allow the individual to express how much they agree or disagree with a particular statement. The total IHSS score is the sum of all item scores (range: 0 to 50), and higher scores indicate more severe symptoms.

Trial Locations

Locations (29)

Takeda Site 27; 🇺🇸 Colorado Springs, Colorado, United States

Takeda Site 29; 🇺🇸 Saint Louis, Missouri, United States

Takeda Site 28; 🇺🇸 Norfolk, Virginia, United States

Takeda Site 26; 🇮🇹 Verona, Veneto, Italy

Takeda Site 11; 🇺🇸 Redwood City, California, United States

Takeda Site 10; 🇺🇸 Santa Ana, California, United States

Takeda Site 19; 🇺🇸 Brandon, Florida, United States

Takeda Site 14; 🇺🇸 Winter Park, Florida, United States

Takeda Site 16; 🇺🇸 Denver, North Carolina, United States

Takeda Site 15; 🇺🇸 Huntersville, North Carolina, United States

Takeda Site 12; 🇺🇸 Cincinnati, Ohio, United States

Takeda Site 17; 🇺🇸 Cincinnati, Ohio, United States

Takeda Site 13; 🇺🇸 Columbia, South Carolina, United States

Takeda Site 18; 🇺🇸 San Antonio, Texas, United States

Takeda Site 1; 🇫🇷 Montpellier, Hrault, France

Takeda Site 3; 🇫🇷 Nantes, Pays De Loire, France

Takeda Site 2; 🇫🇷 Paris, France

Takeda Site 4; 🇭🇰 Sha Tin, Hong Kong

Takeda Site 6; 🇮🇹 Pozzilli, Isernia, Italy

Takeda Site 7; 🇮🇹 Rome, Roma, Italy

Takeda Site 5; 🇮🇹 Bologna, Italy

Takeda Site 25; 🇯🇵 Fukuoka-Shi Hakata-Ku, Fukuoka, Japan

Takeda Site 23; 🇯🇵 Kurume-shi, Fukuoka, Japan

Takeda Site 22; 🇯🇵 Kohoku-ku, Yokohama-Shi, Kanagawa, Japan

Takeda Site 20; 🇯🇵 Kumamoto-shi, Kumamoto, Japan

Takeda Site 21; 🇯🇵 Yodogawa-ku, Osaka-shi, Osaka, Japan

Takeda Site 24; 🇯🇵 Bunkyo-ku, Tokyo, Japan

Takeda Site 9; 🇪🇸 Vitoria, Alava, Spain

Takeda Site 8; 🇪🇸 Madrid, Spain